Last reviewed · How we verify
leuprolide acetate and bicalutamide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
leuprolide acetate and bicalutamide (leuprolide acetate and bicalutamide) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| leuprolide acetate and bicalutamide TARGET | leuprolide acetate and bicalutamide | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- leuprolide acetate and bicalutamide CI watch — RSS
- leuprolide acetate and bicalutamide CI watch — Atom
- leuprolide acetate and bicalutamide CI watch — JSON
- leuprolide acetate and bicalutamide alone — RSS
Cite this brief
Drug Landscape (2026). leuprolide acetate and bicalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprolide-acetate-and-bicalutamide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab